District Court, D. Massachusetts June 2, 2016, MDL No. 09-02067-NMG; Civil Action No. 13-13113-NMG (Painters & Allied Trades District Council 82 Health Care Fund v. Forest Laboratories, Inc.)

Also known as

United States · · · 02-06-2016

*119MEMORANDUM & ORDER

GORTON, J.

This case arises out of the marketing and sales of the related anti-depressant drugs Celexa and Lexapro by defendants Forest Laboratories, Inc. and Forest Pharmaceuticals, Inc. (“defendants” or, collectively, “Forest”). Plaintiff Painters and Allied Trades District Council 82 Health Care Fund (“plaintiff’ or “Painters”) is a health and benefit fund providing benefits to covered members and their families. It acts as a third-party payor (“TPP”) that reimburses the medical expenses of plan members.

Painters alleges that defendants violated the Racketeer Influenced and Corrupt Organizations Act (“RICO”), Minnesota Consumer Fraud Act (“MCFA”), Minnesota Unfair Trade Practices Act (“MUTP”) and Minnesota Deceptive Trade Practices Act by misrepresenting and concealing material information about the efficacy of Celexa and Lexapro in treating major depressive disorder (“MDD”) in pediatric patients.

Pending before the Court is Painters’ motion to certify certain classes (Docket No. 546). For the reasons that follow, that motion will be denied.

I. Background

Celexa and Lexapro are closely-related selective serotonin reuptake inhibitor (“SSRI”) anti-depressants. Forest obtained the approval of the Food and Drug Administration (“FDA”) to market Celexa for adult use in 1998 and Lexapro for adult use in 2002. It later sought to market both drugs for treating MDD in children and adolescents.

A. FDA approval process

In order to obtain FDA approval to market Celexa and Lexapro as effective for pediatric use, Forest had to make a sufficient showing to the FDA that the drugs would be more effective than placebos in treating MDD in pediatric patients. The FDA typically requires the submission of at least two “positive” placebo-controlled clinical trials supporting such use. A “positive” drug study shows statistically significant improvements for patients who are administered the drug rather than a placebo.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.